Literature DB >> 18045853

Plasticity of adenylyl cyclase-related signaling sequelae after long-term morphine treatment.

Michael Shy1, Sumita Chakrabarti, Alan R Gintzler.   

Abstract

Adaptations to long-term morphine treatment resulting in tolerance are protective by counteracting the consequences of sustained opioid receptor activation. Consequently, the manifestation of specific adenylyl cyclase (AC)-related neurochemical sequelae of long-term morphine treatment should depend on the consequences of short-term mu-opioid receptor (MOR) activation. We tested this by comparing complementary chemical sequelae of long-term morphine treatment among cells in which short-term MOR activation inhibited instead of stimulated AC activity. Short-term activation of MOR in Chinese hamster ovary (CHO) cells stably transfected with MOR (MOR-CHO) inhibits AC activity. Long-term morphine treatment of these cells increased AC and Gbeta phosphorylation, membrane protein kinase Cgamma (PKCgamma) translocation, and MOR G(s) association. All converge, shifting the consequences of short-term MOR activation from Galpha(i)/Galpha(o) inhibitory to AC stimulatory signaling. In contrast, overexpression of the Gbetagamma-stimulated AC isoform AC2 (which converted MOR-coupled inhibition to stimulation of AC) eliminated or reversed these adaptations to long-term morphine treatment; it negated the increase in Gbeta phosphorylation and PKCgamma translocation while reversing the increase in AC phosphorylation and MOR G(s) association. These adaptations greatly attenuated MOR-coupled stimulation of AC activity. Altered overexpression of AC protein per se was not a confounding factor because MOR-CHO overexpressing AC1, which is inhibited by short-term MOR activation, manifested adaptations to long-term morphine treatment qualitatively identical with those of MOR-CHO. These results reveal that adaptations elicited by long-term morphine treatment depend on the effects of short-term MOR activation. This dynamic and pliable nature of tolerance mechanisms could represent a new paradigm for pharmacotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045853     DOI: 10.1124/mol.107.042184

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

2.  Pleiotropic opioid regulation of spinal endomorphin 2 release and its adaptations to opioid withdrawal are sexually dimorphic.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; James E Zadina; Tarak Sharma; Alan R Gintzler
Journal:  J Pharmacol Exp Ther       Date:  2011-10-04       Impact factor: 4.030

3.  Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats.

Authors:  Xin Wei; Wei Wei
Journal:  J Anesth       Date:  2011-11-03       Impact factor: 2.078

4.  Subcellular localization of mu-opioid receptor G(s) signaling.

Authors:  Sumita Chakrabarti; Andrew Chang; Alan R Gintzler
Journal:  J Pharmacol Exp Ther       Date:  2010-01-22       Impact factor: 4.030

5.  Contribution of adenylyl cyclase modulation of pre- and postsynaptic GABA neurotransmission to morphine antinociception and tolerance.

Authors:  Erin N Bobeck; QiLiang Chen; Michael M Morgan; Susan L Ingram
Journal:  Neuropsychopharmacology       Date:  2014-03-13       Impact factor: 7.853

6.  Comprehensive Signaling Profiles Reveal Unsuspected Functional Selectivity of δ-Opioid Receptor Agonists and Allow the Identification of Ligands with the Greatest Potential for Inducing Cyclase Superactivation.

Authors:  Ahmed Mansour; Karim Nagi; Paul Dallaire; Viktoriya Lukasheva; Christian Le Gouill; Michel Bouvier; Graciela Pineyro
Journal:  ACS Pharmacol Transl Sci       Date:  2021-09-09

Review 7.  Vitamin D and Its Potential Interplay With Pain Signaling Pathways.

Authors:  Abdella M Habib; Karim Nagi; Nagendra Babu Thillaiappan; VijayaKumar Sukumaran; Saghir Akhtar
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.